Capmatinib for the treatment of METex14 skipping non-small cell lung cancer: retrospective analysis of real-world data from patients receiving compassionate use treatment in Italy

TL;DR

Capmatinib is effective in treating a rare type of lung cancer with METex14 mutations, showing promising results in real-world patient data from Italy.

Contribution

This study provides real-world evidence supporting capmatinib's effectiveness for METex14 skipping NSCLC outside of clinical trials.

Findings

Capmatinib was administered to 53 patients with METex14 skipping NSCLC in Italy.

Most patients started at the full dose and 45.3% discontinued due to disease progression.

The median time to treatment discontinuation was 15.2 months.

Abstract

In patients with advanced non-small cell lung cancer (NSCLC), MET exon 14 (METex14) skipping mutations are rare and are associated with a poor prognosis. Capmatinib, a selective oral MET inhibitor, was recently approved for the treatment of advanced METex14 skipping NSCLC. However, data from real-world experiences are limited. This was a retrospective analysis using real-world data from Italian patients with advanced METex14 skipping NSCLC who had received at least one treatment with immunotherapy and/or platinum-based chemotherapy and received compassionate use treatment with capmatinib. Patient characteristics, treatment details, discontinuations, and adverse events are reported. Overall, 53 patients received capmatinib after receiving treatment with immunotherapy and/or platinum-based chemotherapy in Italy. Patients had a median age of 74 years, mostly metastatic disease (92.5% of patients), and previously received one (66.0%) or more (2: 28.3%; 3: 5.7%) lines of standard treatment (immunotherapy and/or platinum-based chemotherapy). Most patients (98.1%) started treatment with capmatinib at the full recommended dose of 400 mg twice daily and 77.4% did not require a dose reduction. Twenty-four patients (45.3%) discontinued treatment; the most frequent reason for discontinuing treatment was disease progression, with a median estimated time to treatment discontinuation of 15.2 months. This real-world retrospective analysis confirms that capmatinib is a valuable treatment option for difficult-to-treat METex14 skipping NSCLC, in agreement with the data from the registration trial.

Figures